Trials / Completed
CompletedNCT01103791
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Samyang Biopharmaceuticals Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel-PNP | Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-09-01
- Completion
- 2012-04-01
- First posted
- 2010-04-15
- Last updated
- 2017-05-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01103791. Inclusion in this directory is not an endorsement.